Patents Assigned to MedImmune, LLC
-
Patent number: 11939382Abstract: The disclosure relates to binding proteins, including antibodies, that bind to Programmed Death-1 (“PD-1”) and T cell immunoreceptor with Ig and ITIM domains (“TIGIT”). The disclosure also provides compositions comprising such binding proteins and nucleic acid molecules encoding such binding proteins. The disclosure further relates to methods of treating a disorder or condition using such binding proteins.Type: GrantFiled: April 29, 2022Date of Patent: March 26, 2024Assignee: MedImmune, LLCInventors: Yariv Mazor, Yue Wang, Gordon Moody, Deepali Malhotra, Michael Overstreet, Eleanor Clancy-Thompson, Karin Lee, Stacy Pryts, Scott Hammond
-
Patent number: 11932682Abstract: The invention relates to antibodies and binding fragments thereof that are capable of binding to influenza A virus hemagglutinin and neutralizing at least one group 1 subtype and at least 1 group 2 subtype of influenza A virus.Type: GrantFiled: October 21, 2021Date of Patent: March 19, 2024Assignees: MEDIMMUNE, LLC, HUMABS BIOMED SAInventors: Ebony Benjamin, Nicole Kallewaard-LeLay, Josephine Mary McAuliffe, Frances Palmer-Hill, Leslie Wachter, Andy Yuan, Qing Zhu, Davide Corti, Antonio Lanzavecchia, Barbara Guarino, Anna DeMarco
-
Patent number: 11926657Abstract: Binding molecules, including bispecific antibodies that include at least two anti-influenza binding domains are disclosed, including binding molecules having a first binding domain that specifically binds influenza A virus and a second binding domain that specifically binds influenza B virus.Type: GrantFiled: November 11, 2022Date of Patent: March 12, 2024Assignee: MEDIMMUNE, LLCInventors: Nicole Kallewaard-Lelay, Qing Zhu, Godfrey Jonah Rainey, Cuihua Gao, Srinath Kasturirangan, Changshou Gao
-
Patent number: 11912782Abstract: The disclosure is directed to an antibody-drug conjugate (ADC) comprising a monoclonal antibody, or an antigen-binding fragment thereof, directed against B-cell maturation antigen (BCMA) conjugated to a cytotoxin. The disclosure also provides compositions comprising the antibody-drug conjugate and methods of killing multiple myeloma cells (including multiple myeloma stems cells) that express BCMA by contacting multiple myeloma cells with the ADC.Type: GrantFiled: March 29, 2021Date of Patent: February 27, 2024Assignee: MedImmune, LLCInventors: Krista Kinneer, Reena Varkey, Xiaodong Xiao, Elaine M. Hurt, David Tice
-
Patent number: 11845791Abstract: The present disclosure is directed to human GDF-15-binding antibodies and antigen-binding fragments thereof. The antibodies and fragments can be used, for example, to detect human GDF-15 and/or in methods of treating cancer or body weight loss, including cachexia, associated with over-expression of human GDF-15.Type: GrantFiled: March 7, 2022Date of Patent: December 19, 2023Assignee: MEDIMMUNE, LLCInventors: Claire Dobson, Fiona Cusdin, Darren Schofield, Peter Cariuk, Elaine Hurt, Margareta Ek, Carina Johansson, Jenny Sandmark
-
Patent number: 11798653Abstract: Methods for determining treatments for cancer patients are disclosed.Type: GrantFiled: October 18, 2019Date of Patent: October 24, 2023Assignee: MEDIMMUNE, LLCInventors: Li Yu, Harry Yang, Mohammed Dar, Lorin Roskos, Jean-Charles Soria, Charles Ferte, Wei Zhao, Aline Gendrin Brokmann, Jolyon Faria, Pralay Mukhopadhyay, Ikbel Achour
-
Patent number: 11787853Abstract: The invention relates to antibodies and antigen binding fragments thereof that are capable of binding to influenza B virus hemagglutinin (HA) and neutralizing influenza B virus in two phylogenetically distinct lineages. In one embodiment, the antibody or antigen binding fragment is capable of binding to influenza B virus hemagglutinin and neutralizing influenza B virus in Yamagata and Victoria lineages.Type: GrantFiled: October 12, 2021Date of Patent: October 17, 2023Assignees: MEDIMMUNE, LLC, HUMABS BIOMED SAInventors: Nicole Kallewaard-Lelay, Qing Zhu, Ebony Benjamin, Leslie Wachter, Andy Yuan, Josephine Mary Mcauliffe, Davide Corti, Antonio Lanzavecchia
-
Patent number: 11767369Abstract: The present invention provides molecules, including proteins, more particularly, immunoglobulins whose in vivo half-lives are altered (increased or decreased) by the presence of an IgG constant domain, or FcRn binding fragment thereof (e.g., an Fc region or hinge-Fc region) (e.g., from a human IgG, e.g., human IgG1), that have modifications of one or more of amino acid residues in at least the CH3 domain.Type: GrantFiled: September 10, 2019Date of Patent: September 26, 2023Assignee: MedImmune, LLCInventors: Ping Tsui, Martin Borrok, William Dall'Acqua, Yanli Wu, Nurten Beyaz-Kavuncu
-
Patent number: 11759526Abstract: The present invention provides a bioconjugation method and compounds for use therein. The bioconjugation method comprises the step of conjugating a biological molecule containing a first unsaturated functional group with a payload comprising a second unsaturated functional group, wherein the first and second unsaturated functional groups are complementary to each other such that conjugation is a reaction of said functional groups via a Diels-Alder reaction which forms a cyclohexene ring.Type: GrantFiled: May 25, 2018Date of Patent: September 19, 2023Assignees: MedImmune, LLC, The Regents Of The University Of CaliforniaInventors: Ronald James Christie, Changshou Gao, Andre Henri St. Amant, Javier Read de Alaniz
-
Patent number: 11608375Abstract: This disclosure provides ASCT2-binding molecules, e.g., anti-ASCT2 antibodies, and antigen-binding fragments thereof. In certain aspects, the ASCT2-binding molecules are conjugated to cytotoxic drugs, e.g., ASCT2 antibody-drug conjugates (ADCs). In certain aspects, the anti-ASCT2 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects, the ASCT2-binding molecules bind specifically to cells expressing ASCT2, and in some instances, are internalized into the cells. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders characterized by ASCT2 overexpression, e.g., certain types of cancer. In a particular embodiment, the disclosure provides methods for treating cancer using ASCT2 ADCs.Type: GrantFiled: October 1, 2020Date of Patent: March 21, 2023Assignee: MedImmune, LLCInventors: Nabendu Pore, Martin J. Borrok, III, Emil F. Michelotti, David A. Tice, Robert E. Hollingsworth, Chien-Ying Chang, Partha Chowdhury
-
Patent number: 11578119Abstract: The present disclosure is directed to leukotoxin-binding antibodies and antigen-binding fragments thereof. The antibodies and fragments can be used, for example, to detect leukotoxin and/or in methods of treating and preventing Staphylococcus aureus infections.Type: GrantFiled: June 7, 2021Date of Patent: February 14, 2023Assignees: MedImmune LLC, Humabs BioMed SAInventors: Christine Tkaczyk, Bret Sellman, Qun Du, Melissa Damschroder, Davide Corti, Andrea Minola
-
Patent number: 11555175Abstract: This application provides improved cell culture media and cell culture methods comprising N-acetylcysteine. These improved cell culture media and cell culture methods increase cell viability, cellular growth rate and/or reduce cell doubling time of cholesterol auxotrophic cells, myeloma cells, and hybridoma cells.Type: GrantFiled: November 11, 2019Date of Patent: January 17, 2023Assignee: MedImmune, LLCInventors: Brena Williams, Jeong Lee
-
Patent number: 11547756Abstract: Provided herein are methods for treating, reducing or preventing influenza A virus infection in a patient, as well as compositions and articles of manufacture for treating, reducing or preventing influenza A virus infection in a patient.Type: GrantFiled: August 4, 2020Date of Patent: January 10, 2023Assignee: MEDIMMUNE, LLCInventors: Nicole Kallewaard-Lelay, Raburn Mallory, Gabriel Robbie, Song Ren
-
Publication number: 20220411509Abstract: The disclosure relates to binding proteins, including antibodies, that bind to Programmed Death-1 (“PD-1”) and T cell immunoreceptor with Ig and ITIM domains (“TIGIT”). The disclosure also provides compositions comprising such binding proteins and nucleic acid molecules encoding such binding proteins. The disclosure further relates to methods of treating a disorder or condition using such binding proteins.Type: ApplicationFiled: April 29, 2022Publication date: December 29, 2022Applicant: MedImmune, LLCInventors: Yariv MAZOR, Yue WANG, Gordon MOODY, Deepali MALHOTRA, Michael OVERSTREET, Eleanor CLANCY-THOMPSON, Karin LEE, Stacy PRYTS, Scott HAMMOND
-
Patent number: 11482315Abstract: A methodology to track patient usage of an autoinjector (AI) device, and to an external or electronic adaptor (eAdaptor) adapted to be used with the AI are disclosed. The eAdaptor contains sensors (including but not limited to a temperature sensor, a sound sensor, a vibration sensor and a magnetic sensor system), a display, a microprocessor, a real time clock, and communication systems that enables the eAdaptor to capture and confirm autoinjector (AI) use, as well as injection information, and transmit such information wirelessly to a smart phone or any other data receiving system or device. Also disclosed are an internal logic to operate the eAdaptor and a smart device APP that pairs with the internal logic to guide the patients with graphical user interface (GUI) displays on the smart device.Type: GrantFiled: August 9, 2018Date of Patent: October 25, 2022Assignee: MEDIMMUNE, LLCInventors: Michael C. Song, Janardhanan Anand Subramony
-
Patent number: 11447543Abstract: Antibodies and antigen binding fragments thereof directed against Staphylococcus aureus (S. aureus) surface determinant antigens and secreted toxins are disclosed. Methods of detecting, diagnosing and treating S. aureus using the antibodies and antigen binding fragments thereof are also provided.Type: GrantFiled: July 9, 2020Date of Patent: September 20, 2022Assignee: MedImmune, LLCInventors: Bret Sellman, Christine Tkaczyk, Partha S. Chowdhury, Lei Hua, Peter Pavlik, Rebecca Buonpane, Chew-Shun Chang
-
Patent number: 11446377Abstract: Provided herein are methods of treating non-small cell lung cancers comprising administering an effective amount of MEDI4736 or an antigen-binding fragment thereof and tremelimumab or an antigen-binding fragment thereof.Type: GrantFiled: January 24, 2019Date of Patent: September 20, 2022Assignee: MEDIMMUNE, LLCInventors: Rajesh Narwal, Paul Robbins, Joyson Karakunnel, Mohammed Dar
-
Patent number: 11447542Abstract: The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind to Klebsiella pneumoniae O2 and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiella pneumoniae) and/or protects mice from a lethal Klebsiella challenge. The present disclosure also provides methods of reducing Klebsiella (e.g., Klebsiella pneumoniae) or treating or preventing Klebsiella (e.g., Klebsiella pneumoniae) infection in a subject comprising administering the Klebsiella pneumoniae O2 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.Type: GrantFiled: August 4, 2017Date of Patent: September 20, 2022Assignees: MEDIMMUNE, LLC, HUMABS BIOMED SAInventors: Qun Wang, Charles K. Stover, Meghan Pennini, Xiaodong Xiao, Davide Corti, Elisabetta Cameroni, Martina Beltramello, Gilad Kaplan, Anna DeMarco
-
Patent number: 11414477Abstract: The present disclosure relates to a process for preparing antibodies with a defined glycosylation pattern, in particular antibodies with a glycan terminating in an N-acetylglucosamine. The antibodies of the disclosure are suitable for use in a process to conjugate a payload thereto. The disclosure also extends to molecules obtained and obtainable from the process disclosed herein, novel molecules and intermediates, compositions comprising said molecules and uses of the molecules and compositions, particularly in treatment, for example in the treatment of cancer.Type: GrantFiled: January 26, 2017Date of Patent: August 16, 2022Assignee: MedImmune, LLCInventors: Changshou Gao, Pamela Thompson, Dorin Toader, Nazzareno Dimasi
-
Patent number: RE49908Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.Type: GrantFiled: June 30, 2021Date of Patent: April 9, 2024Assignee: MedImmune, LLCInventors: Srinath Kasturirangan, Changshou Gao, Godfrey Rainey, Michelle Morrow, Claire Louise Dobson, Stacey Drabic, Darren Schofield, Gianluca Carlesso, Kristen Pollizzi, Yariv Mazor, Michael Oberst, Scott A. Hammond, Brian Lobo, Prakash Manikwar, Jonathan Seaman, Simon Dovedi, Ronald Herbst